AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30548426
Drug: Carbohydrate (CHO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO; 145 g; n=9)
Trial: 26719947
Drug: Immediate prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate prescription strategy
Trial: 26719947
Drug: No prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prescription strategy
Trial: 26719947
Drug: Delayed prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed prescription collection strategy
Trial: 26719947
Drug: Delayed patient-led
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed patient-led prescription strategy
Trial: 17513173
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg/day until disease progression
Trial: 17513173
Drug: Standard gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard gemcitabine infusion
Trial: 17513173
Drug: PCI gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI gemcitabine 1200 mg/m(2) in a 120-min infusion
Trial: 10452209
Drug: Three telephone
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three telephone calls and oral and written self-care measures for specific side effects
Trial: 10452209
Drug: Higher ESCA
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher ESCA scores before chemotherapy
Trial: 10452209
Drug: Telephone call
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone call and written self-care measures after the second, third, and fourth chemotherapy treatments
Trial: 2180341
Drug: Intravenous ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketanserin (0.14 mg/kg)
Trial: 29085387
Drug: TCMS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCMS plus PEDT combination therapy
Trial: 29085387
Drug: TCMS monotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCMS monotherapy
Trial: 29085387
Drug: PEDT monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEDT monotherapy
Trial: 21792758
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with combined preoperative intraarterial infusion and intravenous chemotherapy before gastrectomy and D2 lymphadenectomy
Trial: 17257877
Drug: Nasal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal vaccine candidate (50 microg HBsAg and 50 microg HBcAg)
Trial: 17257877
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% physiologic saline solution)
Trial: 14665895
Drug: Saw palmetto
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saw palmetto (325 mg daily)
Trial: 11695935
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (200 microg, twice daily for 12 months)
Trial: 11695935
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (200 microg, twice daily for 12 months)
Trial: 8615323
Drug: ACEI (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (5 mg ramipril)
Trial: 21154265
Drug: Citrulline malate
RxNorm normalized name: CITRULLINE MALATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrulline malate (3 g/day)
Trial: 7883113
Drug: Regular beef/pork
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular beef/pork insulin
Trial: 2168836
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride (0.4 mg i.v.)
Trial: 31488484
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual as provided by their general practitioner
Trial: 23627714
Drug: Static magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Static magnetic field (SMF) exposure for 30 minutes, 10 weekly visits; 192 millitesla peak‐to‐peak value
Trial: 23627714
Drug: Non‐magnetized pads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐magnetized pads (sham) for 30 minutes, 10 weekly visits
Trial: 21823377
Drug: Epidural levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural levobupivacaine (15 ml of 0.5%)
Trial: 20368213
Drug: muraglitazar (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: muraglitazar (0.5, 1.5, 5, 10, and 20 mg)
Trial: 20368213
Drug: pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone (15 mg)
Trial: 17111783
Drug: Ribavirin plus
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin plus IFN alpha‐2b 5 MU/day for 1 month followed by IFN alpha‐2b 5 MU thrice weekly for 5 months (Group A)
Trial: 17111783
Drug: Ribavirin plus
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin plus IFN alpha‐2b 5 MU thrice weekly for 6 months (Group B)
Trial: 17111783
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy (Group A)
Trial: 11727875
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (plano lens training)
Trial: 7956629
Drug: Intraperitoneal (IP)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (IP) insulin infusion via programmable implantable pumps
Trial: 7956629
Drug: Multiple subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple subcutaneous (SC) injections
Trial: 21234629
Drug: Multidisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary treatment combining cognitive behavioural therapy (CBT), graded exercise therapy (GET), and pharmacological treatment
Trial: 21234629
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (exercise counselling and pharmacological treatment)
Trial: 8976803
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy plus calcium (Prempak C or Premarin 0.625 mg with 1 g calcium daily)
Trial: 8976803
Drug: Calcium alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium alone (1 g calcium daily)
Trial: 1309303
Drug: Cisplatin (DDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (DDP) administered at 75 mg/m2 in 3-week cycles
Trial: 1309303
Drug: Cisplatin (DDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (DDP) total dose of 450 mg/m2 across all groups
Trial: 1309303
Drug: Cisplatin (DDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (DDP) administration
Trial: 29667066
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg
Trial: 29667066
Drug: Cabozantinib 20
RxNorm normalized name: cabozantinib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 20 mg
Trial: 25773465
Drug: 4.6% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.6% menthol gel
Trial: 25773465
Drug: 10.0% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.0% menthol gel
Trial: 17033530
Drug: 25 to
RxNorm normalized name: Hydrasyn25 Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 to 75 g/day milk-based fortified spreads
Trial: 17033530
Drug: Unsupplemented controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupplemented controls (0 to 5 g FS)
Trial: 10710119
Drug: Fluvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (20 mg/day) + Bezafibrate (400 mg/day)
Trial: 9094876
Drug: High glycogen
RxNorm normalized name: glycogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High glycogen (HG) treatment
Trial: 9094876
Drug: Low glycogen
RxNorm normalized name: glycogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glycogen (LG) treatment
Trial: 23718572
Drug: 4 g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of FIB
Trial: 22854310
Drug: Baclofen (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (titrated up to 60 mg daily or maximum tolerated dose, 48 days)
Trial: 20044530
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (perindopril plus indapamide for those without contraindications)
Trial: 17594201
Drug: garenoxacin 600
RxNorm normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: garenoxacin 600 mg administered alone
Trial: 17594201
Drug: garenoxacin 600
RxNorm normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: garenoxacin 600 mg with Al-Mg antacid
Trial: 17594201
Drug: garenoxacin 600
RxNorm normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: garenoxacin 600 mg administered 2 hours after Al-Mg antacid
Trial: 17594201
Drug: garenoxacin 600
RxNorm normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: garenoxacin 600 mg administered 4 hours after Al-Mg antacid
Trial: 17594201
Drug: garenoxacin 600
RxNorm normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: garenoxacin 600 mg administered 4 hours before Al-Mg antacid
Trial: 17594201
Drug: garenoxacin 600
RxNorm normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: garenoxacin 600 mg administered 2 hours before Al-Mg antacid
Trial: 16170978
Drug: Oral-B Indicator
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B Indicator manual toothbrush
Trial: 11094553
Drug: Invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive treatment (PTCA or CABG)
Trial: 8497491
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil concentrate (FOC) capsules (15 x 1 g/d)
Trial: 8497491
Drug: Placebo (PO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PO) capsules (15 x 1 g/d)
Trial: 28884969
Drug: New procaterol
RxNorm normalized name: procaterol
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New procaterol dry powder inhaler (20 μg)
Trial: 28884969
Drug: Approved procaterol
RxNorm normalized name: procaterol
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approved procaterol dry powder inhaler (20 μg)
Trial: 27443162
Drug: Mixed model
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed model of dose estimates based on current and prior INRs
Trial: 18473867
Drug: Bivalirudin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin plus a provisional GP IIb/IIIa inhibitor
Trial: 16433897
Drug: Intravenous heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heroin administration (67-100-150% of the regular heroin maintenance dose, max single dose 450 mg)
Trial: 16433897
Drug: Heroin inhalation
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heroin inhalation (67-100-150% of the regular heroin maintenance dose, max single dose 450 mg)
Trial: 10674593
Drug: Meclizine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclizine (50 mg pretreatment)
Trial: 10674593
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug (no pretreatment)
Trial: 2821397
Drug: Intravenous CMV
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CMV immune globulin
Trial: 27522394
Drug: Once-daily fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily fixed combination (ODFC) of perindopril 10mg, indapamide 2.5mg, amlodipine 5 or 10mg, and atorvastatin 20mg
Trial: 27522394
Drug: Free-drug combination
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free-drug combination (FDC) of the 3 antihypertensive agents plus atorvastatin 20mg
Trial: 20964767
Drug: 0.5 ml·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml·kg(‐1) of local anesthetic solution
Trial: 20964767
Drug: 0.75 ml·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 ml·kg(‐1) of local anesthetic solution
Trial: 20964767
Drug: 1.0 ml·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml·kg(‐1) of local anesthetic solution
Trial: 21679304
Drug: Vardenafil 10
RxNorm normalized name: vardenafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 10 mg (titrated to 20 or 5 mg after 4 weeks)
Trial: 8039534
Drug: Itraconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (100 mg capsule) after a full meal
Trial: 8039534
Drug: Fluconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (100 mg capsule) after a full meal
Trial: 8039534
Drug: Itraconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (100 mg capsule) on an empty stomach
Trial: 8039534
Drug: Itraconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (100 mg capsule) after a light meal
Trial: 8039534
Drug: Fluconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (100 mg capsule) on an empty stomach
Trial: 8039534
Drug: Fluconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (100 mg capsule) after a light meal
Trial: 3043994
Drug: Indobufen 200
RxNorm normalized name: indobufen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen 200 mg b.i.d.
Trial: 30115530
Drug: Topical pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Topical pirfenidone
Trial: 20538692
Drug: Intravenous MgSO4
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous MgSO4 infusion (80 mmol in 500 mL normal saline per day)
Trial: 20538692
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mL normal saline per day)
Trial: 19001531
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (intensified structured counseling between patient and pharmacist)
Trial: 16946665
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment preference among White patients (55%)
Trial: 16946665
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment preference among White patients (46%)
Trial: 16946665
Drug: Treatment preference
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment preference (unsure) for IDH patients
Trial: 16946665
Drug: Treatment preference
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment preference (surgical) for IDH patients
Trial: 16946665
Drug: Treatment preference
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment preference (unsure) for SpS/DS patients
Trial: 16946665
Drug: Treatment preference
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment preference (surgical) for SpS/DS patients
Trial: 14557432
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (500 IU)
Trial: 14557432
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D (200 IU)
Trial: 6424228
Drug: Low-lactose milk
RxNorm normalized name: CASEINATE/DEXTROSE/LACTOSE/MILK/MINERALS/MULTIVITAMINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-lactose milk (500 ml)
Trial: 6424228
Drug: Low-lactose milk
RxNorm normalized name: CASEINATE/DEXTROSE/LACTOSE/MILK/MINERALS/MULTIVITAMINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-lactose milk (250 ml)
Trial: 19444821
Drug: CYSTUS052 lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYSTUS052 lozenges
Trial: 15855656
Drug: l-homocysteine (65.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-homocysteine (65.1 micromol/kg body wt)
Trial: 9262275
Drug: Long-term pituitary
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term pituitary desensitization followed by gonadotrophin therapy, oocyte retrieval and embryo transfer (group 1)
Trial: 9262275
Drug: Laparoscopic ovarian
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic ovarian electrocautery after pituitary desensitization followed by gonadotrophin therapy, oocyte retrieval and embryo transfer (group 2)
Trial: 8328096
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (25 mg lidocaine and 25 mg prilocaine per gram of cream)
Trial: 341951
Drug: Ampicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (500 mg four times daily)
Trial: 10092259
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily for 7 days
Trial: 10092259
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment and placebo groups
Trial: 7762516
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment for 6 months
Trial: 2102716
Drug: 40 mg/iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/iv of metoclopramide (Group A)
Trial: 2102716
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg iv of metoclopramide and 125 mg/iv of methylprednisolone (Group B)
Trial: 2102716
Drug: 2 mg/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/oral of lorazepam, 125 mg/iv methylprednisolone, and 1 mg/kg/oral of metoclopramide (Group C)
Trial: 22943928
Drug: Micafungin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin at therapeutic dose (300 mg/body)
Trial: 22943928
Drug: Micafungin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin at prophylactic dose (150 mg/body)
Trial: 22943928
Drug: Micafungin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin at lower prophylactic dose (50 mg/body)
Trial: 16023303
Drug: Ceftazidime continuous
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime continuous infusion (60 mg/kg/day following a 20 mg/kg loading dose)
Trial: 16023303
Drug: Ceftazidime intermittent
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime intermittent administration (20 mg/kg every 8 hours)
Trial: 10348466
Drug: L-dopa/carbidopa (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa/carbidopa (750 mg per day)
Trial: 10348466
Drug: L-selegiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-selegiline (10 mg per day)
Trial: 8611072
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE) 50 mg
Trial: 2157983
Drug: Aerosolized amiloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized amiloride (5 mmol per liter; 3.5 ml four times daily)
Trial: 6368246
Drug: azimexon (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azimexon (3 X 600 mg) added to chemotherapy
Trial: 8649942
Drug: Hypovolemic state
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypovolemic state (before therapy)
Trial: 8649942
Drug: Two-week anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-week anticoagulant treatment (dicumarol therapy)
Trial: 24873720
Drug: Davunetide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Davunetide (30 mg twice daily, intranasally)